1
|
Gounou C, Rouyer L, Siegfried G, Harté E, Bouvet F, d'Agata L, Darbo E, Lefeuvre M, Derieppe MA, Bouton L, Mélane M, Chapeau D, Martineau J, Prouzet-Mauleon V, Tan S, Souleyreau W, Saltel F, Argoul F, Khatib AM, Brisson AR, Iggo R, Bouter A. Inhibition of the membrane repair protein annexin-A2 prevents tumor invasion and metastasis. Cell Mol Life Sci 2023; 81:7. [PMID: 38092984 PMCID: PMC10719157 DOI: 10.1007/s00018-023-05049-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Revised: 11/09/2023] [Accepted: 11/11/2023] [Indexed: 12/17/2023]
Abstract
Cancer cells are exposed to major compressive and shearing forces during invasion and metastasis, leading to extensive plasma membrane damage. To survive this mechanical stress, they need to repair membrane injury efficiently. Targeting the membrane repair machinery is thus potentially a new way to prevent invasion and metastasis. We show here that annexin-A2 (ANXA2) is required for membrane repair in invasive breast and pancreatic cancer cells. Mechanistically, we show by fluorescence and electron microscopy that cells fail to reseal shear-stress damaged membrane when ANXA2 is silenced or the protein is inhibited with neutralizing antibody. Silencing of ANXA2 has no effect on proliferation in vitro, and may even accelerate migration in wound healing assays, but reduces tumor cell dissemination in both mice and zebrafish. We expect that inhibiting membrane repair will be particularly effective in aggressive, poor prognosis tumors because they rely on the membrane repair machinery to survive membrane damage during tumor invasion and metastasis. This could be achieved either with anti-ANXA2 antibodies, which have been shown to inhibit metastasis of breast and pancreatic cancer cells, or with small molecule drugs.
Collapse
Affiliation(s)
- C Gounou
- CNRS, Bordeaux INP, CBMN, UMR 5248, University of Bordeaux, Bât. B14, Allée Geoffroy Saint Hilaire, 33600, Pessac, France
| | - L Rouyer
- INSERM, BRIC, U 1312, University of Bordeaux, 33000, Bordeaux, France
| | - G Siegfried
- INSERM, BRIC, U 1312, University of Bordeaux, 33000, Bordeaux, France
- XenoFish, B2 Ouest, Allée Geoffroy St Hilaire CS50023, 33615, Pessac, France
| | - E Harté
- CNRS, LOMA, UMR 5798, University of Bordeaux, 33400, Talence, France
| | - F Bouvet
- CNRS, Bordeaux INP, CBMN, UMR 5248, University of Bordeaux, Bât. B14, Allée Geoffroy Saint Hilaire, 33600, Pessac, France
| | - L d'Agata
- CNRS, Bordeaux INP, CBMN, UMR 5248, University of Bordeaux, Bât. B14, Allée Geoffroy Saint Hilaire, 33600, Pessac, France
| | - E Darbo
- INSERM, BRIC, U 1312, University of Bordeaux, 33000, Bordeaux, France
| | - M Lefeuvre
- CNRS, Bordeaux INP, CBMN, UMR 5248, University of Bordeaux, Bât. B14, Allée Geoffroy Saint Hilaire, 33600, Pessac, France
| | - M A Derieppe
- Animalerie Mutualisée, Service Commun des Animaleries, University of Bordeaux, 33000, Bordeaux, France
| | - L Bouton
- INSERM, BRIC, U 1312, University of Bordeaux, 33000, Bordeaux, France
| | - M Mélane
- CNRS, LOMA, UMR 5798, University of Bordeaux, 33400, Talence, France
| | - D Chapeau
- CNRS, Bordeaux INP, CBMN, UMR 5248, University of Bordeaux, Bât. B14, Allée Geoffroy Saint Hilaire, 33600, Pessac, France
| | - J Martineau
- Animalerie Mutualisée, Service Commun des Animaleries, University of Bordeaux, 33000, Bordeaux, France
| | - V Prouzet-Mauleon
- INSERM, BRIC, U 1312, University of Bordeaux, 33000, Bordeaux, France
- CRISPRedit, TBMcore, UAR CNRS 3427, Inserm US 005, University of Bordeaux, Bordeaux, France
| | - S Tan
- CNRS, Bordeaux INP, CBMN, UMR 5248, University of Bordeaux, Bât. B14, Allée Geoffroy Saint Hilaire, 33600, Pessac, France
| | - W Souleyreau
- INSERM, BRIC, U 1312, University of Bordeaux, 33000, Bordeaux, France
| | - F Saltel
- INSERM, BRIC, U 1312, University of Bordeaux, 33000, Bordeaux, France
| | - F Argoul
- CNRS, LOMA, UMR 5798, University of Bordeaux, 33400, Talence, France
| | - A M Khatib
- INSERM, BRIC, U 1312, University of Bordeaux, 33000, Bordeaux, France
- XenoFish, B2 Ouest, Allée Geoffroy St Hilaire CS50023, 33615, Pessac, France
- Bergonié Institute, Bordeaux, France
| | - A R Brisson
- CNRS, Bordeaux INP, CBMN, UMR 5248, University of Bordeaux, Bât. B14, Allée Geoffroy Saint Hilaire, 33600, Pessac, France
| | - R Iggo
- INSERM, BRIC, U 1312, University of Bordeaux, 33000, Bordeaux, France
| | - A Bouter
- CNRS, Bordeaux INP, CBMN, UMR 5248, University of Bordeaux, Bât. B14, Allée Geoffroy Saint Hilaire, 33600, Pessac, France.
| |
Collapse
|
2
|
Bonnefoi H, Richard E, Grellety T, Velasco V, MacGrogan G, Iggo R. Abstract P4-06-02: The mammary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tumours. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-06-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was not presented at the symposium.
Collapse
Affiliation(s)
- H Bonnefoi
- Bergonie Cancer Institute, INSERM U1218, University of Bordeaux, Bordeaux, France
| | - E Richard
- Bergonie Cancer Institute, INSERM U1218, University of Bordeaux, Bordeaux, France
| | - T Grellety
- Bergonie Cancer Institute, INSERM U1218, University of Bordeaux, Bordeaux, France
| | - V Velasco
- Bergonie Cancer Institute, INSERM U1218, University of Bordeaux, Bordeaux, France
| | - G MacGrogan
- Bergonie Cancer Institute, INSERM U1218, University of Bordeaux, Bordeaux, France
| | - R Iggo
- Bergonie Cancer Institute, INSERM U1218, University of Bordeaux, Bordeaux, France
| |
Collapse
|
3
|
Quenel-Tueux N, Dalenc F, Bachelot T, Pulido M, Bonnefoi H, Mauriac L, Madranges N, Iggo R, Lortal B, Tunon de Lara C, Campo P, Debled M. Abstract P1-15-01: A randomized phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally-advanced hormone-receptor-positive breast cancer: First results. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p1-15-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Neoadjuvant endocrine therapy improves surgical outcomes for postmenopausal women with hormone-receptor-positive (HR+) breast cancer. We performed a prospective trial aiming to assess the response rate of an aromatase inhibitor (anastrozole) or an antiestrogen (fulvestrant) and to better understand the mechanisms of sensitivity or resistance to therapy. Translational research was carried out on DNA and mRNA from samples taken from the tumor at baseline and surgery.
Patients and methods: 120 post-menopausal patients (pts) from 3 centers were enrolled in this multicenter randomized phase II study between Jan 2008 to Aug 2012. They were randomly assigned to receive either neoadjuvant anastrozole (arm A: 1 mg/day) or fulvestrant (arm B: 500 mg with a loading dose during the first month then q4W) for 6 months. The primary endpoint was objective response rate (ORR) determined by clinical palpation based on RECIST criteria at 6 months. Secondary endpoints include ORR by ultrasound and mammography, toxicity, rate of breast-conserving surgery (BCS), pathological response using the Sataloff classification, and disease-free and overall survivals (DFS, OS). Follow-up is planned for 5 years.
Results: 118 pts were evaluable for toxicity. 108 pts were evaluable for response (arm A: 56, Arm B: 52). Baseline characteristics in arm A vs. arm B were well balanced: median age (69 vs. 71yrs), median clinical size (45 vs. 50 mm), histologic grades I-II (56 pts, 91.8% vs. 52 pts, 88.2%), grade III (3 pts, 4.9% vs. 5 pts, 8.5%), and HER2-positivity (4 pts, 6.6% vs. 3 pts, 5.1%).
The most common Grade 1-2 treatment-related toxicities were hot flushes (21.7% and 17.2% in arms A and B respectively), asthenia (10.0% vs. 29.3%) and musculoskeletal symptoms (38.3% vs. 20.7%). Grade 3 Toxicity was reported for one pt (joint pain) in arm A and 3 pts (hot flushes) in arm B. No treatment-related serious adverse events were reported.
ORR was 58.9% (95%CI[45-72]) in arm A and 53.8% (95%CI[39-68]) in arm B; 33 pts in arm A underwent BCS (58.9%) vs. 26 (50%) in arm B. 1 pt in arm A and 3 pts in arm B did not undergo surgery.
TA and TB pathological responses were observed in 24 pts (42.9%) in arm A and 13 pts (25.0%) in arm B. Ki67 values were analyzed before treatment and at surgery in 39 cases (arm A) and 34 cases (arm B). We observed a decrease of Ki67 in 76.9% of pts in arm A and 73.5% in arm B.
Genomic analysis showing the appearance of acquired changes after treatment will be reported in another presentation.
Conclusions: Both anastrozole and fulvestrant seem to be effective neoadjuvant endocrine therapies and may offer an attractive option with low toxicity profile for HR+ post-menopausal women. Both treatments have similar efficacy in terms of both clinical impact and Ki67 decrease.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-15-01.
Collapse
Affiliation(s)
- N Quenel-Tueux
- Institut Bergonie, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Leon Berard, Lyon, France
| | - F Dalenc
- Institut Bergonie, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Leon Berard, Lyon, France
| | - T Bachelot
- Institut Bergonie, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Leon Berard, Lyon, France
| | - M Pulido
- Institut Bergonie, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Leon Berard, Lyon, France
| | - H Bonnefoi
- Institut Bergonie, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Leon Berard, Lyon, France
| | - L Mauriac
- Institut Bergonie, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Leon Berard, Lyon, France
| | - N Madranges
- Institut Bergonie, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Leon Berard, Lyon, France
| | - R Iggo
- Institut Bergonie, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Leon Berard, Lyon, France
| | - B Lortal
- Institut Bergonie, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Leon Berard, Lyon, France
| | - C Tunon de Lara
- Institut Bergonie, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Leon Berard, Lyon, France
| | - P Campo
- Institut Bergonie, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Leon Berard, Lyon, France
| | - M Debled
- Institut Bergonie, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Leon Berard, Lyon, France
| |
Collapse
|
4
|
Richard E, Schmidt X, MacGrogan G, Iggo R. R161: Modèle de greffe orthotopique de cellules humaines dans la glande mammaire de souris immunodéficientes NSG. Bull Cancer 2010. [DOI: 10.1016/s0007-4551(15)31082-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
5
|
Bonnefoi HR, Bogaerts J, Piccart M, Mauriac L, Fumoleau P, Jassem J, Becette V, Cameron DA, Bergh J, Iggo R. Phase III trial (EORTC 10994/BIG 00-01) assessing the value of p53 using a functional assay to predict sensitivity to a taxane versus nontaxane primary chemotherapy in breast cancer: Final analysis. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.18_suppl.lba503] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA503 Background: Predictive markers of response to chemotherapy are lacking. Preclinical data suggest that p53 mutated tumors are resistant to anthracyclines and sensitive to taxanes. However, clinical data are contradictory. Using a functional yeast assay to detect biologically important mutations, this study tested the hypothesis that docetaxel confers a greater advantage over anthracyclines in p53 mutated tumors (mut) than p53 wild type (wt). Methods: Patients (pts) with locally advanced/inflammatory or large operable tumors were randomized to either a standard anthracycline regimen (arm A) or a taxane-based treatment (arm B). In arm A pts received 6 cycles of FEC 100, or tailored FEC + G-CSF (Swedish cohort). In arm B docetaxel (T) 100mg/m2 was given for 3 cycles, followed by 3 cycles of epirubicin 90mg/m2and T 75mg/m2 q3 weeks (T-ET). After chemotherapy, pts underwent surgery followed by radiotherapy. Endocrine therapy and/or trastuzumab were given according to each center's policy. Fresh frozen tumor biopsies were mandatory before starting chemotherapy: frozen sections were examined centrally and the p53 test was done when the invasive tumor cell content was > 20%. cDNA derived from tumor-extracted RNA was transfected into yeast (Flaman et al. PNAS 1995): tumors were deemed p53 wt when there were < 20% red colonies (background) and p53 mut > 20%. The three co-primary comparisons for the endpoint of progression-free survival (PFS) were between arms A and B in p53 mut, p53 wt, and the entire trial population, each at a p=0.02. The sample size gave sufficient power for an interaction test for outcomes between p53 mut and wt at p<0.05. Results: From April 2001 to November 2006, 1,856 patients were included. A total of 386 pts (21%) were ineligible (including 292 pts with <20% tumor cells and 67 without sample). No unexpected toxicity was observed. At the time of analysis 675 events were registered after a median follow-up time of 57 months. The results are summarized below. Conclusions: p53 is not a predictive factor of response or resistance to taxanes, although it is, as expected, prognostic (<0.001). PFS is not statistically significantly different between FEC and T-ET arms at the 2% cutoff level. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- H. R. Bonnefoi
- Geneva University Hospitals, Geneva, Switzerland; Bergoniá Institute, Bordeaux, France; European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Centre Georges-Francois Leclerc, Dijon, France; Medical University of Gdansk, Gdansk, Poland; Centre Rená Huguenin, Saint-Cloud, France; Edinburgh University, Edinburgh, Scotland; Karolinska Institutet, University Hospital, Stockholm, Sweden; Swiss Institute for Experimental Cancer Research and
| | - J. Bogaerts
- Geneva University Hospitals, Geneva, Switzerland; Bergoniá Institute, Bordeaux, France; European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Centre Georges-Francois Leclerc, Dijon, France; Medical University of Gdansk, Gdansk, Poland; Centre Rená Huguenin, Saint-Cloud, France; Edinburgh University, Edinburgh, Scotland; Karolinska Institutet, University Hospital, Stockholm, Sweden; Swiss Institute for Experimental Cancer Research and
| | - M. Piccart
- Geneva University Hospitals, Geneva, Switzerland; Bergoniá Institute, Bordeaux, France; European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Centre Georges-Francois Leclerc, Dijon, France; Medical University of Gdansk, Gdansk, Poland; Centre Rená Huguenin, Saint-Cloud, France; Edinburgh University, Edinburgh, Scotland; Karolinska Institutet, University Hospital, Stockholm, Sweden; Swiss Institute for Experimental Cancer Research and
| | - L. Mauriac
- Geneva University Hospitals, Geneva, Switzerland; Bergoniá Institute, Bordeaux, France; European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Centre Georges-Francois Leclerc, Dijon, France; Medical University of Gdansk, Gdansk, Poland; Centre Rená Huguenin, Saint-Cloud, France; Edinburgh University, Edinburgh, Scotland; Karolinska Institutet, University Hospital, Stockholm, Sweden; Swiss Institute for Experimental Cancer Research and
| | - P. Fumoleau
- Geneva University Hospitals, Geneva, Switzerland; Bergoniá Institute, Bordeaux, France; European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Centre Georges-Francois Leclerc, Dijon, France; Medical University of Gdansk, Gdansk, Poland; Centre Rená Huguenin, Saint-Cloud, France; Edinburgh University, Edinburgh, Scotland; Karolinska Institutet, University Hospital, Stockholm, Sweden; Swiss Institute for Experimental Cancer Research and
| | - J. Jassem
- Geneva University Hospitals, Geneva, Switzerland; Bergoniá Institute, Bordeaux, France; European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Centre Georges-Francois Leclerc, Dijon, France; Medical University of Gdansk, Gdansk, Poland; Centre Rená Huguenin, Saint-Cloud, France; Edinburgh University, Edinburgh, Scotland; Karolinska Institutet, University Hospital, Stockholm, Sweden; Swiss Institute for Experimental Cancer Research and
| | - V. Becette
- Geneva University Hospitals, Geneva, Switzerland; Bergoniá Institute, Bordeaux, France; European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Centre Georges-Francois Leclerc, Dijon, France; Medical University of Gdansk, Gdansk, Poland; Centre Rená Huguenin, Saint-Cloud, France; Edinburgh University, Edinburgh, Scotland; Karolinska Institutet, University Hospital, Stockholm, Sweden; Swiss Institute for Experimental Cancer Research and
| | - D. A. Cameron
- Geneva University Hospitals, Geneva, Switzerland; Bergoniá Institute, Bordeaux, France; European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Centre Georges-Francois Leclerc, Dijon, France; Medical University of Gdansk, Gdansk, Poland; Centre Rená Huguenin, Saint-Cloud, France; Edinburgh University, Edinburgh, Scotland; Karolinska Institutet, University Hospital, Stockholm, Sweden; Swiss Institute for Experimental Cancer Research and
| | - J. Bergh
- Geneva University Hospitals, Geneva, Switzerland; Bergoniá Institute, Bordeaux, France; European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Centre Georges-Francois Leclerc, Dijon, France; Medical University of Gdansk, Gdansk, Poland; Centre Rená Huguenin, Saint-Cloud, France; Edinburgh University, Edinburgh, Scotland; Karolinska Institutet, University Hospital, Stockholm, Sweden; Swiss Institute for Experimental Cancer Research and
| | - R. Iggo
- Geneva University Hospitals, Geneva, Switzerland; Bergoniá Institute, Bordeaux, France; European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Centre Georges-Francois Leclerc, Dijon, France; Medical University of Gdansk, Gdansk, Poland; Centre Rená Huguenin, Saint-Cloud, France; Edinburgh University, Edinburgh, Scotland; Karolinska Institutet, University Hospital, Stockholm, Sweden; Swiss Institute for Experimental Cancer Research and
| | | |
Collapse
|
6
|
Iggo R, Farmer P, Wirapati P, Anderle P, Delorenzi M, Bogaerts J, Piccart M, Cameron D, Bergh J, Bonnefoi H. 223 A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)70250-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
7
|
Bonnefoi H, Zimmer AS, Piccart M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Welnicka-Jaskiewicz M, Cufer T, Blot E, Becette V, Bogaerts J, André S, Cameron D, Bergh J, Iggo R. P53 functional assay in yeast: evaluation in 1856 patients in a large prospective clinical trial (EORTC 10994/BIG 00-01). Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-1067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #1067
Background:Although mutations in the p53 gene can occur in 20-30% of sporadic breast cancer, and are associated with other poor prognostic factors, there is no clear evidence as to whether p53 status should influence therapy. Immunohistochemistry has been demonstrated to be an inferior method compared with sequencing, but the optimal technique to assess the functional p53 status is not known. The yeast test is a functional assay which tests the transcriptional competence of p53, and detects biologically important mutations. Here we present the results of p53 evaluation using this method in a prospective study.
 Material and methods: EORTC 10994/BIG 00-01 trial is a randomized trial comparing the neoadjuvant use of an anthracycline-based regimen with a taxane-containing regimen in patients with large operable or locally advanced breast cancers. Fresh frozen tumour biopsies were mandatory before starting chemotherapy. Frozen sections were examined centrally and the p53 test was done if the invasive tumour cell content was above 20%. RNA extract was used to assess p53 status: p53 wild type tumours were defined as tumours whose cDNA transfected in yeast gave less than 20% red colonies (background); p53 mutated tumours gave 20% or more red colonies.
 Results: The trial accrual was completed in November 2006 after inclusion of 1856 patients. There was no frozen sample available in 70 patients. In 276 patients the % of tumour cells was <20. The p53 test failed in 62 patients, generally because the quality or quantity of RNA was too low for RT-PCR. P53 was successfully assessed in 1458 patients: 661 (45%) tumours are p53 mutated and 797 (55%) are p53 wt. p53 mutated and wild type tumours were grade III in 40% (265/661) and 19% (153/797), respectively, and estrogen receptor negative in 41% (270/661) and 14.5% (116/797), respectively. We did not see any correlation between p53 status and tumour size or nodal status at diagnosis. HER2 status data are being collected.
 Conclusion: P53 status has been successfully evaluated using a yeast assay in 78.5% (1458/1856) of cases in the context of a multicenter trial. In indirect comparisons the frequency of patients with functionally altered p53 status is higher than with sequenced based methods. Our results confirm an association between p53 mutation and high grade or estrogen receptor negative status, but not with age, tumour size or clinical nodal status. More data regarding the quality and quantity of RNA collected will be presented at the meeting.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1067.
Collapse
Affiliation(s)
- H Bonnefoi
- 1 European Organization for Research and Treatment of Cancer, Brussels, Belgium
- 2 Swiss Group for Clinical Cancer Research, Bern, Switzerland
| | - AS Zimmer
- 1 European Organization for Research and Treatment of Cancer, Brussels, Belgium
| | - M Piccart
- 1 European Organization for Research and Treatment of Cancer, Brussels, Belgium
| | - L Mauriac
- 1 European Organization for Research and Treatment of Cancer, Brussels, Belgium
| | - M Campone
- 1 European Organization for Research and Treatment of Cancer, Brussels, Belgium
| | - M Tubiana-Hulin
- 1 European Organization for Research and Treatment of Cancer, Brussels, Belgium
| | - T Petit
- 1 European Organization for Research and Treatment of Cancer, Brussels, Belgium
| | - P Rouanet
- 1 European Organization for Research and Treatment of Cancer, Brussels, Belgium
| | | | - T Cufer
- 1 European Organization for Research and Treatment of Cancer, Brussels, Belgium
| | - E Blot
- 1 European Organization for Research and Treatment of Cancer, Brussels, Belgium
| | - V Becette
- 1 European Organization for Research and Treatment of Cancer, Brussels, Belgium
| | - J Bogaerts
- 1 European Organization for Research and Treatment of Cancer, Brussels, Belgium
| | - S André
- 3 Swiss Institute for Experimental Cancer Research/National Centre of Competence in Research, Epalinges, Switzerland
| | - D Cameron
- 4 Anglo-Celtic Cooperative Oncology Group, Edinburgh, United Kingdom
| | - J Bergh
- 5 Swedish Breast Cancer Group/Karolinska Institutet, Stockholm, Sweden
| | - R Iggo
- 3 Swiss Institute for Experimental Cancer Research/National Centre of Competence in Research, Epalinges, Switzerland
| |
Collapse
|
8
|
Bazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R, Iggo R, Homicsko K, Fisher KD, Halldén G, Mautner V, Shen Y, Seymour LW. Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus. Hum Gene Ther 2008; 19:873-86. [PMID: 18710328 DOI: 10.1089/hum.2008.047] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Oncolytic viruses are regulated by the tumor phenotype to replicate and lyse cancer cells selectively. To identify optimal strategies for breast cancer we compared five adenoviruses with distinct regulatory mechanisms: Ad-dl922-947 (targets G1-S checkpoint); Ad-Onyx-015 and Ad-Onyx-017 (target p53/mRNA export); Ad-vKH1 (targets Wnt pathway), and AdEHE2F (targets estrogen receptor/G1-S checkpoint/hypoxic signaling). The quantity of virus required to kill 50% of breast cancer cells after 6 days (EC(50), plaque-forming units per cell) was measured. The most potent virus was Ad-dl922-947 (EC(50), 0.01-5.4 in SkBr3, MDA-231, MDA-468, MCF7, and ZR75.1 cells), followed by wild-type (Ad-WT; EC(50), 0.3-5.5) and AdEHE2F (EC(50), 1.4-3.9). Ad-vKH1 (EC(50), 7.2-72.1), Ad-Onyx-017 (EC(50), 8.4-167), and Ad-Onyx-015 (EC(50), 17.7-377) showed less activity. Most viruses showed limited cytotoxicity in normal human cells, including breast epithelium MCF10A (EC(50), >722) and fibroblasts (EC(50), >192) and only moderate cytotoxicity in normal microvascular endothelial cells (HMVECs; EC(50), 42.8-149), except Ad-dl922-947, which was active in HMVECs (EC(50), 1.6). After injection into MDA-231 xenografts, Ad-WT, AdEHE2F, and Ad-dl922-947 showed replication, assessed by hexon staining and quantitative polymerase chain reaction measurement of viral DNA, and significantly inhibited tumor growth, leading to extended survival. After intravenous injection Ad-dl922-947 showed DNA replication (233% of the injected dose was measured in liver after 3 days) whereas AdEHE2F did not. Overall, AdEHE2F showed the best combination of low toxicity in normal cells and high activity in breast cancer in vitro and in vivo, suggesting that molecular targeting using estrogen response elements, hypoxia response elements, and a dysregulated G1-S checkpoint is a promising strategy for virotherapy of breast cancer.
Collapse
Affiliation(s)
- M Bazan-Peregrino
- Department of Clinical Pharmacology, University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, United Kingdom
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Merron A, Peerlinck I, Martin-Duque P, Burnet J, Quintanilla M, Mather S, Hingorani M, Harrington K, Iggo R, Vassaux G. SPECT/CT imaging of oncolytic adenovirus propagation in tumours in vivo using the Na/I symporter as a reporter gene. Gene Ther 2007; 14:1731-8. [PMID: 17960161 DOI: 10.1038/sj.gt.3303043] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Oncolytic adenoviruses have shown some promise in cancer gene therapy. However, their efficacy in clinical trials is often limited, and additional therapeutic interventions have been proposed to increase their efficacies. In this context, molecular imaging of viral spread in tumours could provide unique information to rationalize the timing of these combinations. Here, we use the human sodium iodide symporter (hNIS) as a reporter gene in wild-type and replication-selective adenoviruses. By design, hNIS cDNA is positioned in the E3 region in a wild-type adenovirus type 5 (AdIP1) and in an adenovirus in which a promoter from the human telomerase gene (RNA component) drives E1 expression (AdAM6). Viruses show functional hNIS expression and replication in vitro and kinetics of spread of the different viruses in tumour xenografts are visualized in vivo using a small animal nano-SPECT/CT camera. The time required to reach maximal spread is 48 h for AdIP1 and 72 h for AdAM6 suggesting that genetic engineering of adenoviruses can affect their kinetics of spread in tumours. Considering that this methodology is potentially clinically applicable, we conclude that hNIS-mediated imaging of viral spread in tumours may be an important tool for combined anticancer therapies involving replicating adenoviruses
Collapse
Affiliation(s)
- A Merron
- Centre for Molecular Oncology, Institute of Cancer, Queen Mary's School of Medicine and Dentistry, London, UK
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Bonnefoi H, Potti A, Mauriac L, Tubiana-Hulin M, Campone M, Cameron D, Bergh J, Delorenzi M, Nevins J, Iggo R. 5BA Clinical validation of in vitro drug sensitivity microarray data: regimen-specific signatures predict pathological complete response to neo-adjuvant chemotherapy for breast cancer in a randomized trial (EORTC 10994/BIG 00-01). EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70105-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
11
|
Bonnefoi HR, Potti A, Piccart M, Mauriac L, Tubiana-Hulin M, Cameron D, Bergh J, Delorenzi M, Nevins JR, Iggo R. Clinical validation of in vitro drug sensitivity microarray data: Regimen-specific signatures predict pathological complete response to neo-adjuvant chemotherapy for breast cancer in a randomized trial (EORTC 10994/BIG 00–01). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
544 Background: We previously described gene expression signatures that predict sensitivity to common chemotherapeutic agents and published promising results of their applicability in patients (Nature Med 2006). The goal of this study was to confirm their validity in a larger series of breast cancer patients with hormone-receptor negative (HR negative) since these tumours are more sensitive to chemotherapy. We used pathological complete response as a surrogate for chemosensitivity. We analyzed samples from a subset of patients included in a recently completed large neoadjuvant phase III trial. The trial compares a non-taxane regimen (fluorouracil + epirubicin + cyclophosphamide × 6; FEC arm) with a taxane regimen (docetaxel × 3 then epirubicin + docetaxel × 3; T->ET arm). Methods: RNA prepared from frozen samples obtained at diagnosis were hybridized to Affymetrix arrays. In vitro single agent signatures generated using a metagene approach were combined to obtain a FEC and a T->ET regimen-specific signatures. Predictions were blinded to patient outcome. With both signatures we calculated the receiver operating curve, its AUC, and the cut-point with maximal Youden index- accuracy, positive predictive value (PPV), sensitivity (Sens), negative predictive value (NPV) and specificity (Spec). Results: Samples from 124 patients (55 pCR) with HR negative tumours underwent a successful gene-expression array: 65 patients were treated in FEC arm and 59 patients in T->ET arm. The results are summarized below. Conclusions: We have validated the approach of using regimen-specific genomic signatures developed in vitro, in the context of a multicenter randomized trial. These results support the activation of a prospective trial comparing the conventional random choice of chemotherapy versus a specific array based approach. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- H. R. Bonnefoi
- Geneva University Hospital, Geneva, Switzerland; Duke University Medical Center, Durham, NC; Institut Jules Bordet, Brussels, Belgium; Institut Bergoni, Bordeaux, France; Centre Rene Huguenin, St. Cloud, France; Western General Hospital, Edinburgh, United Kingdom; Karolinska Institutet and Karolinska Univ Hospital, Stockholm, Sweden; Swiss Institute for Bioinformatics (SIB), Epalinges-Lausanne, Switzerland; Swiss Instit for Experim Cancer Research (ISREC), Epalinges-Lausanne, Switzerland
| | - A. Potti
- Geneva University Hospital, Geneva, Switzerland; Duke University Medical Center, Durham, NC; Institut Jules Bordet, Brussels, Belgium; Institut Bergoni, Bordeaux, France; Centre Rene Huguenin, St. Cloud, France; Western General Hospital, Edinburgh, United Kingdom; Karolinska Institutet and Karolinska Univ Hospital, Stockholm, Sweden; Swiss Institute for Bioinformatics (SIB), Epalinges-Lausanne, Switzerland; Swiss Instit for Experim Cancer Research (ISREC), Epalinges-Lausanne, Switzerland
| | - M. Piccart
- Geneva University Hospital, Geneva, Switzerland; Duke University Medical Center, Durham, NC; Institut Jules Bordet, Brussels, Belgium; Institut Bergoni, Bordeaux, France; Centre Rene Huguenin, St. Cloud, France; Western General Hospital, Edinburgh, United Kingdom; Karolinska Institutet and Karolinska Univ Hospital, Stockholm, Sweden; Swiss Institute for Bioinformatics (SIB), Epalinges-Lausanne, Switzerland; Swiss Instit for Experim Cancer Research (ISREC), Epalinges-Lausanne, Switzerland
| | - L. Mauriac
- Geneva University Hospital, Geneva, Switzerland; Duke University Medical Center, Durham, NC; Institut Jules Bordet, Brussels, Belgium; Institut Bergoni, Bordeaux, France; Centre Rene Huguenin, St. Cloud, France; Western General Hospital, Edinburgh, United Kingdom; Karolinska Institutet and Karolinska Univ Hospital, Stockholm, Sweden; Swiss Institute for Bioinformatics (SIB), Epalinges-Lausanne, Switzerland; Swiss Instit for Experim Cancer Research (ISREC), Epalinges-Lausanne, Switzerland
| | - M. Tubiana-Hulin
- Geneva University Hospital, Geneva, Switzerland; Duke University Medical Center, Durham, NC; Institut Jules Bordet, Brussels, Belgium; Institut Bergoni, Bordeaux, France; Centre Rene Huguenin, St. Cloud, France; Western General Hospital, Edinburgh, United Kingdom; Karolinska Institutet and Karolinska Univ Hospital, Stockholm, Sweden; Swiss Institute for Bioinformatics (SIB), Epalinges-Lausanne, Switzerland; Swiss Instit for Experim Cancer Research (ISREC), Epalinges-Lausanne, Switzerland
| | - D. Cameron
- Geneva University Hospital, Geneva, Switzerland; Duke University Medical Center, Durham, NC; Institut Jules Bordet, Brussels, Belgium; Institut Bergoni, Bordeaux, France; Centre Rene Huguenin, St. Cloud, France; Western General Hospital, Edinburgh, United Kingdom; Karolinska Institutet and Karolinska Univ Hospital, Stockholm, Sweden; Swiss Institute for Bioinformatics (SIB), Epalinges-Lausanne, Switzerland; Swiss Instit for Experim Cancer Research (ISREC), Epalinges-Lausanne, Switzerland
| | - J. Bergh
- Geneva University Hospital, Geneva, Switzerland; Duke University Medical Center, Durham, NC; Institut Jules Bordet, Brussels, Belgium; Institut Bergoni, Bordeaux, France; Centre Rene Huguenin, St. Cloud, France; Western General Hospital, Edinburgh, United Kingdom; Karolinska Institutet and Karolinska Univ Hospital, Stockholm, Sweden; Swiss Institute for Bioinformatics (SIB), Epalinges-Lausanne, Switzerland; Swiss Instit for Experim Cancer Research (ISREC), Epalinges-Lausanne, Switzerland
| | - M. Delorenzi
- Geneva University Hospital, Geneva, Switzerland; Duke University Medical Center, Durham, NC; Institut Jules Bordet, Brussels, Belgium; Institut Bergoni, Bordeaux, France; Centre Rene Huguenin, St. Cloud, France; Western General Hospital, Edinburgh, United Kingdom; Karolinska Institutet and Karolinska Univ Hospital, Stockholm, Sweden; Swiss Institute for Bioinformatics (SIB), Epalinges-Lausanne, Switzerland; Swiss Instit for Experim Cancer Research (ISREC), Epalinges-Lausanne, Switzerland
| | - J. R. Nevins
- Geneva University Hospital, Geneva, Switzerland; Duke University Medical Center, Durham, NC; Institut Jules Bordet, Brussels, Belgium; Institut Bergoni, Bordeaux, France; Centre Rene Huguenin, St. Cloud, France; Western General Hospital, Edinburgh, United Kingdom; Karolinska Institutet and Karolinska Univ Hospital, Stockholm, Sweden; Swiss Institute for Bioinformatics (SIB), Epalinges-Lausanne, Switzerland; Swiss Instit for Experim Cancer Research (ISREC), Epalinges-Lausanne, Switzerland
| | - R. Iggo
- Geneva University Hospital, Geneva, Switzerland; Duke University Medical Center, Durham, NC; Institut Jules Bordet, Brussels, Belgium; Institut Bergoni, Bordeaux, France; Centre Rene Huguenin, St. Cloud, France; Western General Hospital, Edinburgh, United Kingdom; Karolinska Institutet and Karolinska Univ Hospital, Stockholm, Sweden; Swiss Institute for Bioinformatics (SIB), Epalinges-Lausanne, Switzerland; Swiss Instit for Experim Cancer Research (ISREC), Epalinges-Lausanne, Switzerland
| |
Collapse
|
12
|
Abstract
The Wnt signaling pathway is activated by mutations in the adenomatous polyposis coli (APC) or beta-catenin genes in most colon cancers, leading to the transactivation of promoters containing binding sites for the Tcf/LEF family of transcription factors. We have previously shown that it is possible to confer colon cancer specificity on autonomous parvoviruses by inserting Tcf sites into the viral P4 promoter. The mutant Tcf promoters were responsive to activation of the Wnt pathway but the viruses replicated poorly. We show here that reduction of the number of Tcf sites from four to two leads to an increase in the efficiency of replication and toxicity of the viruses in Co115 colon cancer cells, with only a small reduction in selectivity for cells with an active Wnt signaling pathway. Despite this improvement, virus production by most colon cancer cells remained low. Analysis of parental phH1 virus infection of SW480 colon cancer cells showed that the nonstructural and capsid proteins were expressed, but single stranded DNA and progeny virus were not produced. This defect reflects the dependence of autonomous parvoviruses on host functions for many steps in their replication cycle and represents a major limitation to the use of selectively replicating parvoviruses for colon cancer therapy.
Collapse
Affiliation(s)
- M Malerba
- NCCR Molecular Oncology, Swiss Institute for Experimental Cancer Research, ISREC, Epalinges, Switzerland
| | | | | | | |
Collapse
|
13
|
Bonnefoi H, Farmer P, Becette V, Piccart M, Campone M, Mauriac L, Jassem J, Bergh J, Cameron D, Iggo R. Stroma related gene signature predicts sensitivity to epirubicin containing neoadjuvant chemotherapy. A microarray study of 102 patients included in EORTC 10994/BIG 00-01 trial. EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)80240-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
14
|
Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, MacGrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Fiche M, Brisken C, Delorenzi M, Iggo R. Identification of molecular apocrine breast tumours by microarray analysis. Breast Cancer Res 2005. [PMCID: PMC4233543 DOI: 10.1186/bcr1122] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
15
|
Abstract
Clinical studies with oncolytic adenoviruses have shown that existing viruses are safe but lack efficacy. To selectively increase the toxicity of oncolytic adenoviruses targeting colon tumours, we have inserted the yeast cytosine deaminase gene (yCD) after the fibre gene in the major late transcript. yCD was expressed using either an internal ribosome entry site (IRES) or by alternative splicing of a new exon analogous to the Ad41 long fibre exon. The IRES-CD virus gave higher yCD expression on Western blots. Both approaches result in yCD expression restricted to the period after viral DNA replication. Viral burst size was reduced by less than approximately 10-fold by 5-fluorocytosine (5-FC), showing that expression of yCD as a late gene is compatible with virus replication. Cytopathic effect assays in colon cancer cell lines showed that both yCD viruses have approximately 10-fold increased toxicity in the presence of the prodrug 5-FC, which is converted to 5-fluorouracil (5-FU) by yCD. Toxicity was higher following addition of 5-FC immediately after infection. The largest gain in toxicity was seen in HT29 colon cancer cells, which are the least permissive colon cancer cells for the parental virus, indicating that the new 5-FC/yCD viruses may have broader applications for colon cancer therapy than their predecessors.
Collapse
Affiliation(s)
- C Fuerer
- Oncogene Group, NCCR Molecular Oncology, Swiss Institute for Experimental Cancer Research (ISREC), Epalinges, Switzerland
| | | |
Collapse
|
16
|
Bonnefoi H, Ducraux A, Movarekhi S, Pelte MF, Bongard S, Lurati E, Iggo R. p53 as a potential predictive factor of response to chemotherapy: feasibility of p53 assessment using a functional test in yeast from trucut biopsies in breast cancer patients. Br J Cancer 2002; 86:750-5. [PMID: 11875738 PMCID: PMC2375302 DOI: 10.1038/sj.bjc.6600105] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2001] [Revised: 11/15/2001] [Accepted: 12/04/2001] [Indexed: 11/15/2022] Open
Abstract
Assessment of the predictive value of p53 requires the testing of large numbers of samples from patients enrolled in prospective phase III clinical trials. The goal of this study was to determine whether p53 status can be determined by p53 yeast functional assay using the limiting amounts of material that can typically be obtained in prospective phase III trials (particularly when chemotherapy is given before surgery). All patients presenting with a clinically palpable tumour which could be considered large enough to perform a trucut biopsy (> or =2 cm breast tumour) were eligible for this study. Two trucut biopsies and one incisional biopsy were performed on the surgical specimens (mastectomy or tumourectomy). Samples were snap frozen and cryostat sections were taken for histology and p53 testing. Thirty patients were included. Three samples out of 90 failed to give any p53 PCR products, probably because these samples contained almost entirely fibrous tissue. Of the 87 samples that could be tested, the incisional and trucut biopsies results were fully concordant in every case. p53 could be defined in 97% of patients by double trucut biopsy. Eight out of 30 tumours tested were mutant for p53 (27%). p53 status can be reliably determined by yeast assay from single frozen sections of trucut biopsies. Histological examination before p53 testing is essential to exclude cases where the p53 result may reflect only the status of the normal cells in the biopsy.
Collapse
Affiliation(s)
- H Bonnefoi
- Département de Gynécologie Obstétrique, Hôpitaux Universitaires de Genève, Boulevard de la Cluse 32, CH-1211 Genève 14-Switzerland
| | | | | | | | | | | | | |
Collapse
|
17
|
Fuerer C, Iggo R. Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway. Gene Ther 2002; 9:270-81. [PMID: 11896466 DOI: 10.1038/sj.gt.3301651] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2001] [Accepted: 12/11/2001] [Indexed: 11/09/2022]
Abstract
Mutation of the adenomatous polyposis coli and beta-catenin genes in colon cancer leads to constitutive activation of transcription from promoters containing binding sites for Tcf/LEF transcription factors. We have constructed adenoviruses with Tcf binding sites in the early promoters, in order to target viral replication to colon tumours. Tcf regulation of the E1A promoter confers a 100-fold selectivity for cells with activated wnt signalling in viral burst and cytopathic effect assays. p300 is a coactivator for beta-catenin, and E1A inhibits Tcf-dependent transcription through sequestration of p300, but mutation of the p300 binding site in E1A leads to a 10-fold reduction in cytopathic effect of all of the Tcf-regulated viruses. When Tcf sites are inserted in the E1A, E1B, E2 and E4 promoters the viruses show up to 100 000-fold selectivity for cells with activated wnt signalling.
Collapse
Affiliation(s)
- C Fuerer
- Oncogene Group, Swiss Institute for Experimental Cancer Research (ISREC), Epalinges, Switzerland
| | | |
Collapse
|
18
|
Campomenosi P, Monti P, Aprile A, Abbondandolo A, Frebourg T, Gold B, Crook T, Inga A, Resnick MA, Iggo R, Fronza G. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene 2001; 20:3573-9. [PMID: 11429705 DOI: 10.1038/sj.onc.1204468] [Citation(s) in RCA: 104] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2000] [Revised: 02/22/2001] [Accepted: 03/15/2001] [Indexed: 11/09/2022]
Abstract
The human p53 protein acts mainly as a stress inducible transcription factor transactivating several genes involved in cell cycle arrest (e.g. p21) or apoptosis (e.g. Bax, PIG3). Roughly half of all human tumours contains p53 missense mutations. Virtually all tumour-derived p53 mutants are unable to activate Bax transcription but some retain the ability to activate p21 transcription. Identification of these mutants may have valuable clinical implications. We have determined the transactivation ability of 77 p53 mutants using reporter yeast strains containing a p53-regulated ADE2 gene whose promoter is regulated by p53 responsive elements derived from the regulatory region of the p21, Bax and PIG3 genes. We also assessed the influence of temperature on transactivation. Our results indicate that a significant proportion of mutants [16/77 (21%); 10/64 (16%) considering only tumour-derived mutants] are transcriptionally active, especially with the p21 promoter. Discriminant mutants preferentially affect less conserved (P<0.04, Fisher's exact test), more rarely mutated (P<0.006, Fisher's exact test) amino acids. Temperature sensitivity is frequently observed, but is more common among discriminant than non-discriminant mutants (P<0.003, Fisher's exact test). Finally, we extended the analysis to a group of mutants isolated in BRCA-associated tumours that surprisingly were indistinguishable from wild type in standard transcription, growth suppression and apoptosis assays in human cells, but showed gain of function in transformation assays. The incidence of transcriptionally active mutations among this group was significantly higher than in the panel of mutants studied previously (P<0.001, Fisher's exact test). Since it is not possible to predict the behaviour of a mutant from first principles, we propose that the yeast assay be used to compile a functional p53 database and fill the gap between the biophysical, pharmacological and clinical fields.
Collapse
Affiliation(s)
- P Campomenosi
- Mutagenesis-Laboratory, National Cancer Research Institute (IST), Largo R. Benzi, 10, 16132-Genova, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Meinhold-Heerlein I, Ninci E, Ikenberg H, Brandstetter T, Ihling C, Schwenk I, Straub A, Schmitt B, Bettendorf H, Iggo R, Bauknecht T. Evaluation of methods to detect p53 mutations in ovarian cancer. Oncology 2001; 60:176-88. [PMID: 11244334 DOI: 10.1159/000055316] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
OBJECTIVE The p53 status is increasingly regarded as a marker predictive of response to particular cancer therapies, but for this approach it is self-evident that the p53 status must be determined correctly. METHODS We have tested ovarian cancers with single-strand conformation polymorphism analysis (SSCP), immunohistochemical staining with DO-1 anti-p53 antibody (IHC), and yeast p53 functional assay (FASAY). RESULTS These techniques commonly used to detect p53 mutations showed important differences in their sensitivity. Of 53 tumors tested with three indirect techniques, 27 (50%), 33 (62%) and 41 (77%) were positive by SSCP, IHC, and FASAY, respectively. In a subset of 32 tumors strongly suspected of containing mutations, 25 (78%), 26 (81%), 29 (91%) and 30 (94%) were positive by SSCP, immunostaining, DNA sequencing and yeast assay, respectively. CONCLUSIONS Under comparable routine conditions, the FASAY reached the highest sensitivity. Since no single technique detected all mutations, we recommend the use of at least two different techniques in situations where the p53 status will affect patient management.
Collapse
|
20
|
Abstract
Despite important advances in understanding the molecular basis of cancer, few treatments have been devised which rationally target known causal oncogenic defects. Selectively replicating viruses have a major advantage over nonreplicating viruses to target these defects because the therapeutic effect of the injected virus is augmented by virus produced within the tumor. To permit rational targeting of colon tumors, we have developed replicating adenoviruses that express the viral E1B and E2 genes from promoters controlled by the Tcf4 transcription factor. Tcf4 is constitutively activated by mutations in the adenomatous polyposis coli and beta-catenin genes in virtually all colon tumors and is constitutively repressed by Groucho and CtBP in normal tissue. The Tcf-E2 and Tcf-E1B promoters are active in many, but not all, cell lines with activation of the wnt pathway. Viruses with Tcf regulation of E2 expression replicate normally in SW480 colon cancer cells but show a 50- to 100-fold decrease in replication in H1299 lung cancer cells and WI38 normal fibroblasts. Activation of wnt signaling by transduction of a stable beta-catenin mutant into normal fibroblasts renders the cells permissive for virus replication. Insertion of Tcf4 sites in the E1B promoter has only small effects on replication in vitro but significantly reduces the inflammatory response in a rodent lung model in vivo. Replicating adenoviruses with Tcf regulation of both E1B and E2 transcription are potentially useful for the treatment of liver metastases from colorectal tumors, but additional changes will be required to produce a virus that can be used to treat all colon tumors.
Collapse
Affiliation(s)
- M Brunori
- Swiss Institute for Experimental Cancer Research (ISREC), 1066 Epalinges, Switzerland
| | | | | | | |
Collapse
|
21
|
Chappuis PO, Estreicher A, Dieterich B, Bonnefoi H, Otter M, Sappino AP, Iggo R. Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay. Int J Cancer 1999; 84:587-93. [PMID: 10567903 DOI: 10.1002/(sici)1097-0215(19991222)84:6<587::aid-ijc8>3.0.co;2-8] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
p53 status was tested in 180 patients with primary breast cancer using a yeast functional assay. Mutations were identified in 32% of cases. Only half were point missense mutations; the remainder were nonsense, insertion, deletion and splice site mutations. Twenty-two percent of mutations were located outside exons 5-8. For a median follow-up of 88 months, survival analysis showed that p53 mutation conferred a worse prognosis in the whole population and the node-positive subgroup but not in node-negative patients. p53 status, tumour size >2 cm, axillary lymph node metastasis and high histological grade were major adverse risk factors in univariate analysis. Multivariate analysis of 153 patients for whom full data were available showed that p53 status contributed prognostic information when tumour size and lymph node status were taken into account but not when histological grade was included. p53 status thus contributes only limited new prognostic information in breast cancer when established prognostic factors are taken into account. Int. J. Cancer (Pred. Oncol.) 84:587-593, 1999.
Collapse
Affiliation(s)
- P O Chappuis
- Division of Oncology, Department of Medicine, Hôpitaux Universitaires, Geneva, Switzerland
| | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
We have developed a new approach to photodynamic therapy based on adenoviral transduction of the rate-limiting enzyme in heme synthesis. Conventional phototherapy uses porphyrin-based chemical photosensitisers, including delta-aminolaevulinic acid (ALA) which is converted to protoporphyrin IX (PpIX) by the enzymes of the heme biosynthetic pathway. The lack of a specific mechanism for targeting chemical photosensitisers and PpIX to tumour cells means that therapeutic irradiation can damage normal tissue and exposure to sunlight following treatment can cause severe burns. The rate limiting enzyme in PpIX synthesis is ALA-synthase (ALA-S). We have developed a new yeast vector system for manipulation of the adeno- virus genome and used it to construct a virus expressing a mutant form of ALA-S lacking the iron response elements which regulate ALA-S translation and the heme regulatory motifs which regulate import of ALA-S into mitochondria. The virus induces a large increase in PpIX expression and confers photosensitivity on cultured cells. Unlike conventional photodynamic therapy, a viral approach makes it possible to restrict photosensitivity by biological rather than purely physical or chemical means. As with HSV thymidine kinase, ALA-S expression is a general mechanism for sensitisation to a therapeutic agent which can easily be adapted to whatever means of gene delivery is most effective.
Collapse
Affiliation(s)
- J Gagnebin
- Swiss Institute for Experimental Cancer Research (ISREC), Epalinges, Switzerland
| | | | | | | | | | | |
Collapse
|
23
|
Yuan ZQ, Wong N, Foulkes WD, Alpert L, Manganaro F, Andreutti-Zaugg C, Iggo R, Anthony K, Hsieh E, Redston M, Pinsky L, Trifiro M, Gordon PH, Lasko D. A missense mutation in both hMSH2 and APC in an Ashkenazi Jewish HNPCC kindred: implications for clinical screening. J Med Genet 1999; 36:790-3. [PMID: 10528862 PMCID: PMC3622028 DOI: 10.1136/jmg.36.10.792] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
|
24
|
Abstract
p53 mutants in tumours have a reduced affinity for DNA and a reduced ability to induce apoptosis. We describe a mutant with the opposite phenotype, an increased affinity for some p53-binding sites and an increased ability to induce apoptosis. The apoptotic function requires transcription activation by p53. The mutant has an altered sequence specificity and selectively fails to activate MDM2 transcription. Loss of MDM2 feedback results in overexpression of the mutant, but the mutant kills better than wild-type p53 even in MDM2-null cells. Thus the apoptotic phenotype is due to a combination of decreased MDM2 feedback control and increased or unbalanced expression of other apoptosis-inducing p53 target genes. To identify these genes, DNA chips were screened using RNA from cells expressing the apoptosis-inducing mutant, 121F, and a sequence-specificity mutant with the reciprocal phenotype, 277R. Two potential new mediators of p53-dependent apoptosis were identified, Rad and PIR121, which are induced better by 121F than wild-type p53 and not induced by 277R. The 121F mutant kills untransformed MDM2-null but not wild-type mouse embryo fibroblasts and kills tumour cells irrespective of p53 status. It may thus expand the range of tumours which can be treated by p53 gene therapy.
Collapse
Affiliation(s)
- E Saller
- Swiss Institute for Experimental Cancer Research (ISREC), CH-1066 Epalinges, Switzerland
| | | | | | | | | | | | | |
Collapse
|
25
|
Fujimoto H, Sasaki J, Matsumoto M, Suga M, Ando Y, Iggo R, Tada M, Saya H, Ando M. Significant correlation of nitric oxide synthase activity and p53 gene mutation in stage I lung adenocarcinoma. Jpn J Cancer Res 1998; 89:696-702. [PMID: 9738975 PMCID: PMC5921893 DOI: 10.1111/j.1349-7006.1998.tb03273.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Nitric oxide (NO) and its derivatives can directly cause DNA damage and mutation in vitro and may play a role in the multistage carcinogenic process. It has been reported that NO induces mutation in the p53 tumor suppressor gene; we therefore analyzed the relationship between NO synthase (NOS) activity and p53 gene status in early-stage lung adenocarcinoma. Surgical samples were classified into two categories: 14 lung adenocarcinomas with high NOS activity (>25 pmol/min/g tissue, category A), and 16 with low NOS activity (<25 pmol/min/g tissue, category B). A yeast functional assay for p53 mutations disclosed a red colony that corresponded to a mutation in the p53 gene in 8 cases (57.1%) in category A and 3 cases (18.8%) in category B, the frequency being significantly higher in the former (P<0.05). A p53 DNA sequence analysis revealed that 5 of the 8 p53 mutation-positive samples in category A had a G:C-to-T:A transversion, which is reported to be a major target of NO. The mechanism of carcinogenesis of adenocarcinoma is not fully understood, but these results suggest that an excess of endogenously formed NO may induce a p53 gene mutation containing mainly G:C-to-T:A transversion in the early stage of lung adenocarcinoma. Our results suggest that NO has potential mutagenic and carcinogenic activity, and may play important roles in human lung adenocarcinoma.
Collapse
Affiliation(s)
- H Fujimoto
- First Department of Internal Medicine, Kumamoto University School of Medicine
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
|
27
|
Flaman JM, Robert V, Lenglet S, Moreau V, Iggo R, Frebourg T. Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast. Oncogene 1998; 16:1369-72. [PMID: 9546439 DOI: 10.1038/sj.onc.1201889] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Recent studies have suggested that a rare class of p53 mutants found in tumours has a subtle transcriptional defect affecting bax induction but not p21 induction. We have therefore developed simple functional assays in yeast which can be used to identify these mutants. Analysis of 51 different mutations observed in human tumours showed that all mutants tested scored as mutant with the bax reporter strain but nine scored as wild-type with the p21 reporter strain. These results, which can be explained by the lower affinity of the p53 protein for the bax site, may suggest that p21 is not the key target of p53 mutations in tumours. Since p21 status has recently been shown to modulate the chemotherapeutic and radiotherapeutic sensitivities of cancerous cells, the functional assays described here may have important clinical implications.
Collapse
Affiliation(s)
- J M Flaman
- Laboratoire de Génétique Moléculaire, CHU de Rouen, France
| | | | | | | | | | | |
Collapse
|
28
|
Gagnebin J, Kovar H, Kajava AV, Estreicher A, Jug G, Monnier P, Iggo R. Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity. Oncogene 1998; 16:685-90. [PMID: 9482117 DOI: 10.1038/sj.onc.1201568] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
p53 triple mutants (120N/121G/277H, 120H/121G/ 277H, 120S/121G/277H and 120H/121G/277Y) have altered sequence specificity in bandshift assays in vitro and transcription assays in vivo. These mutants activate transcription from the site TTT CATG AAA but not from wild type sites. The triple mutants activate more strongly than p53 with a single 277Y mutation. The TTT site matches the wild type p53 consensus at only 4/10 positions and is not recognised by wild type p53. 277Y mutations have been described in human tumours, and Ewing tumour cells expressing this mutant from the endogenous p53 locus selectively activate transcription from transfected luciferase reporters regulated by TTT-mutant p53 binding sites. p53 mutants with altered sequence specificity have potential advantages for cancer gene therapy: if used to activate transcription of conditionally toxic genes they would allow tumour-targeting by p53, which acts as a sensor for the malignant state, but place control over cell killing in the hands of the clinician. Rare tumours expressing such mutants from the endogenous p53 locus could be targeted directly with p53-regulated suicide vectors, but for most tumours both the p53 mutant and the reporter would need to be encoded by the virus.
Collapse
Affiliation(s)
- J Gagnebin
- Swiss Institute for Experimental Cancer Research (ISREC), Epalinges, Switzerland
| | | | | | | | | | | | | |
Collapse
|
29
|
Kashiwazaki H, Tonoki H, Tada M, Chiba I, Shindoh M, Totsuka Y, Iggo R, Moriuchi T. High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay. Oncogene 1997; 15:2667-74. [PMID: 9400993 DOI: 10.1038/sj.onc.1201438] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
To determine the timing and actual incidence of p53 mutations in oral epithelial lesions, we examined 33 primary squamous cell carcinomas (SCCs), 14 dysplasias and six hyperplasias from Japanese patients by a combination of yeast functional assay and DNA sequencing. The assay detects mutations of p53 mRNA between codons 67 and 347 on the basis of the DNA-binding activity of the protein. Twenty-six SCCs (79%) and five dysplasias (36%) were positive for p53 mutation, while all six hyperplasias were negative for the mutation. Human papillomavirus type 16 E6 mRNA was detected in one of seven p53 mutation-negative SCCs by reverse transcription polymerase chain reaction (RT-PCR). We further examined p53 mutations in 17 Sri Lankan oral SCCs using the yeast functional assay and the single-strand conformation polymorphism analysis of PCR-amplified DNA fragments (PCR-SSCP) of exon 5-8. The mutations were confirmed by DNA sequencing and the detection sensitivity was compared between the two methods. Six samples (35%) were positive for p53 mutation in PCR-SSCP analysis, while nine samples (53%) were positive in yeast functional assay. This suggests that the incidence of p53 mutations has been considerably underestimated in the conventional SSCP analysis. The present data indicate that p53 mutations are extremely frequent in oral cancers in the Japanese, and suggest that the timing and significance of p53 mutation in oral tumor progression vary in different ethnic populations and areas.
Collapse
Affiliation(s)
- H Kashiwazaki
- Division of Cell Biology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Inga A, Cresta S, Monti P, Aprile A, Scott G, Abbondandolo A, Iggo R, Fronza G. Simple identification of dominant p53 mutants by a yeast functional assay. Carcinogenesis 1997; 18:2019-21. [PMID: 9364015 DOI: 10.1093/carcin/18.10.2019] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Analysis of families with germline p53 mutations shows that the mutant p53 allele behaves as a dominant oncogene at the genetic level, although it behaves as a recessive oncogene at the cellular level, since tumours invariably show mutation or loss of both wild-type alleles. At the biochemical level it is possible that some clinically important mutant p53 proteins may be carcinogenic through a dominant mechanism. We show that p53 mutants can be readily classified according to their dominant potential using a simple yeast functional assay. Wild-type p53 is constitutively expressed from a TRP1 vector, p53 mutants are expressed from an otherwise identical LEU2 vector and net transcriptional activity is scored using an ADE2-based reporter. Twenty seven p53 mutants were tested: 19 were recessive, i.e. gave white colonies, and eight showed dominant activity, i.e. gave pink/red colonies. This simple assay should facilitate studies on p53 dominance.
Collapse
Affiliation(s)
- A Inga
- CSTA-Mutagenesis Laboratory, National Institute for Research on Cancer (IST), Genova, Italy
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Andreutti-Zaugg C, Scott RJ, Iggo R. Inhibition of nonsense-mediated messenger RNA decay in clinical samples facilitates detection of human MSH2 mutations with an in vivo fusion protein assay and conventional techniques. Cancer Res 1997; 57:3288-93. [PMID: 9242462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Germ-line mutations in the human MSH2 (hMSH2) gene account for about 40% of known defects in kindreds with hereditary nonpolyposis colon cancer. We describe a simple fusion protein assay for detection of hMSH2 nonsense mutations in yeast. Detection of nonsense mutations with this assay is severely compromised in many cases by nonsense-mediated mRNA decay, a physiological process that destabilizes the mutant RNA. Triggering of nonsense-mediated decay requires mRNA scanning by the ribosome to detect the stop codon. We show that treatment of cells with the translation inhibitor puromycin suppresses nonsense-mediated decay and facilitates the detection of nonsense mutations in clinical samples by cDNA sequencing, in vitro protein truncation tests, and the yeast fusion protein assay. Given the prevalence of chain-terminating mutations in human disease genes, puromycin treatment of blood samples should improve the signal-to-noise ratio and hence the sensitivity of many RNA-based diagnostic tests. Paradoxically, the yeast hMSH2::ADE2 fusion protein assay also detects some in-frame mutations, presumably through an effect on the folding of the fusion protein.
Collapse
|
32
|
Inga A, Iannone R, Monti P, Molina F, Bolognesi M, Abbondandolo A, Iggo R, Fronza G. Determining mutational fingerprints at the human p53 locus with a yeast functional assay: a new tool for molecular epidemiology. Oncogene 1997; 14:1307-13. [PMID: 9178891 DOI: 10.1038/sj.onc.1200952] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
In order to isolate experimentally induced p53 mutations, a yeast expression vector harbouring a human wild-type p53 cDNA was treated in vitro with the antineoplastic drug chloroethyl-cyclohexyl-nitroso-urea (CCNU) and transfected into a yeast strain containing the ADE2 gene regulated by a p53-responsive promoter. p53 mutations were identified in 32 out of 39 plasmids rescued from independent ade- transformants. Ninety-two percent of CCNU induced mutations were GC-targeted single base pair substitutions, and GC > AT transitions represented 73% of all single base pair substitutions. In 70% of the cases the mutated G was preceded 5' by a purine. The distribution of the mutations along the p53 cDNA was not random: positions 734 and 785 appeared as CCNU mutational hotspots (n=3, P<0.0003) and CCNU induced only GC > AT transitions at those positions. The features of these CCNU-induced mutations are consistent with the hypothesis that O6-alkylguanine is the major causative lesion. One third of the CCNU-induced mutants were absent from a huge collection of 4496 p53 mutations in human tumours and cell lines, thus demonstrating that CCNU has a mutational spectrum which is uniquely different from that of naturally selected mutations. This strategy allows direct comparison of observed natural mutation spectra with experimentally induced mutation spectra and opens the way to a more rigorous approach in the field of molecular epidemiology.
Collapse
Affiliation(s)
- A Inga
- CSTA-Mutagenesis Laboratory, National Institute for Research on Cancer (IST), Genova, Italy
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Abstract
Cytotoxic T lymphocytes (CTL) recognize peptides presented at the cell surface in association with major histocompatibility complex (MHC) class I molecules. The finding that peptides binding to MHC class I molecules share common amino acid motifs renders feasible the selection of antigenic peptides by simply scanning protein sequences, and thus, provides the possibility of inducing CTL to pre-defined specificities. Tumor cells possess antigens known to generate MHC class I-restricted CD8+ CTL responses. Thus, these antigens represent good targets to induce tumor-specific immunity. Among these antigens, the p53 tumor suppressor gene product is an attractive candidate for cancer immunotherapy. Mutations in the p53 gene have been found to be very frequently associated with a malignant transformation and often lead to p53 protein overexpression. Thus, we investigated the possibility of inducing CTL to wild-type or mutant p53 peptides in a BALB/c (H-2d) mouse model. Peptides possessing the H2-Kd binding motif were selected and tested for binding to the H-2Kd molecules in vitro. Synthetic peptides p53(122-130) wild-type or "mutant" (Lys --> Glu substitution at position 129) were shown to be the best binder peptides and were tested for their immunogenicity in mice. H-2Kd-restricted p53-specific CD8+ CTL were generated following immunization of mice with either wild-type (wt) p53(122-130) or mutant (mut) p53(122-130) (E129) peptides. Only low-affinity CTL can be obtained by immunization with the wt sequence. In contrast, CTL elicited with the mut peptide recognized the mut sequence at a 10-100-fold lower concentration. This indicates that CTL elicited with the mut peptide recognized the mut sequence very efficiently, whereas the wt sequence is poorly recognized, if at all. Taken together, these results thus suggest that p53-specific tumor immunotherapy may be successful only if the mutated protein is taken into consideration.
Collapse
Affiliation(s)
- S Bertholet
- Institute of Biochemistry, University of Lausanne, Epalinges, Switzerland
| | | | | |
Collapse
|
34
|
Tada M, Sawamura Y, Abe H, Iggo R. Homozygous p53 gene mutation in a radiation-induced glioblastoma 10 years after treatment for an intracranial germ cell tumor: case report. Neurosurgery 1997; 40:393-6. [PMID: 9007876 DOI: 10.1097/00006123-199702000-00034] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
OBJECTIVE Radiation-induced glioma is a rare but serious complication of radiotherapy. Underlying radiation-induced mutations in oncogenes or tumor suppressor genes have not previously been described. CLINICAL PRESENTATION A 16-year-old female patient developed a glioblastoma in the right frontal lobe 10 years after treatment of a suprasellar germ cell tumor with 50 Gy ionizing radiation. The glioblastoma was undetectable on a high-resolution magnetic resonance image obtained 3 months before diagnosis. METHODS AND RESULTS A p53 functional assay was used to examine the transcriptional competence of the p53 tumor suppressor gene. This assay scores the content of mutant p53 alleles in tumor and blood samples quantitatively as a percentage of red yeast colonies. The glioblastoma contained 95% mutant p53 alleles, whereas blood from the patient and her parents contained only normal background levels of red colonies. Sequencing revealed that the mutation in the tumor was a 3-base pair deletion affecting codons 238 and 239. Intragenic deletion within the p53 deoxyribonucleic acid binding domain is uncommon in sporadic tumors but would be entirely consistent with misrepair of a radiation-induced double-strand deoxyribonucleic acid break in this case. CONCLUSION This is the first case in which a causative underlying genetic event has been identified in a radiation-induced glioblastoma. We infer that mutation of one p53 allele occurred at the time of radiotherapy, and the sudden appearance of the tumor 10 years later occurred after loss of the remaining wild-type allele and/or other genetic alterations, such as chromosome 10 loss and epidermal growth factor receptor gene amplification.
Collapse
Affiliation(s)
- M Tada
- Department of Neurosurgery, University of Hokkaido School of Medicine, Sapporo, Japan
| | | | | | | |
Collapse
|
35
|
Waridel F, Estreicher A, Bron L, Flaman JM, Fontolliet C, Monnier P, Frebourg T, Iggo R. Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract. Oncogene 1997; 14:163-9. [PMID: 9010218 DOI: 10.1038/sj.onc.1200812] [Citation(s) in RCA: 129] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Field cancerisation of the aerodigestive tract is caused by chronic exposure to alcohol and tobacco, but the nature of the genetic alterations preceding overt malignancy is unknown. To identify potential field changes we have used a functional assay which tests the transcriptional competence of human p53 expressed in yeast. To increase the sensitivity and reliability of the technique for samples containing under 20% mutant p53, the 5' and 3'-ends of the p53 cDNA were examined separately. With this split form of the assay the tissue p53 mRNA acts as its own control for RNA quality. Mutations were detected in 87% (46/53) of tumours, reflecting the high sensitivity of the technique. Multiple biopsies of histologically normal tissue from the upper aero-digestive tract were tested and clonal p53 mutations were identified in 76% (38/50) of biopsies from patients presenting with multiple tumours compared with 32% (38/117) of biopsies from patients presenting with single tumours (P<0.000001). All patients (16/16) presenting with multiple tumours had at least one positive biopsy, compared with only 53% (19/36) of patients presenting with single tumours (P <0.001). This defines expansion of multiple clones of mutant p53-containing cells as an important biological mechanism of field cancerisation, and provides a means to identify patients likely to benefit from intensive screening for the development of new head and neck tumours.
Collapse
Affiliation(s)
- F Waridel
- Oncogene Group, Swiss Institute for Experimental Cancer Research (ISREC), Epalinges
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Cottu PH, Muzeau F, Estreicher A, Fléjou JF, Iggo R, Thomas G, Hamelin R. Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines. Oncogene 1996; 13:2727-30. [PMID: 9000147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The high point mutation rate of replication error-prone (RER+) cells could theoretically lead to inactivation of the p53 gene by polyclonal mutations, which might explain the conflicting results that have been published on the p53 status of RER+ colon cancers. To address this issue, we tested the p53 status of 21 human colorectal cancer cell lines, including four showing microsatellite instability (RER+ phenotype). Denaturing gradient gel electrophoresis (DGGE) followed by sequencing showed that all four RER+ cell lines were wild type for p53 while 15 of the 17 RER- cell lines contained p53 mutations (P=0.001). Eight cell lines (four RER+ and four RER-) were analysed using three complementary methods to test more rigorously the polyclonal mutation hypothesis. (i) Of 87 single-cell clones (seven to 14 per cell line) examined by DGGE, only those derived from known p53 mutant cell lines showed altered profiles. (ii) Antibody DO-7 stained more than 80% of nuclei from the p53 mutant cell lines, but only 15% of nuclei from the RER+ cell lines. (iii) A yeast functional assay which can simultaneously detect polyclonal mutations at over 500 different sites in the p53 cDNA scored all four RER+ cell lines as containing only transcriptionally active p53. These data thus do not support the polyclonal mutation hypothesis and instead suggest that mismatch repair deficiency provides a p53-independent pathway for development of colorectal cancers.
Collapse
Affiliation(s)
- P H Cottu
- Inserm U 434, Génétique des Tumeurs, Institut Curie, Paris, France
| | | | | | | | | | | | | |
Collapse
|
37
|
Affiliation(s)
- F Waridel
- Otorhinolaryngology Service, University Hospital, Lausanne, Switzerland
| | | |
Collapse
|
38
|
|
39
|
Guillou L, Estreicher A, Chaubert P, Hurlimann J, Kurt AM, Metthez G, Iggo R, Gray AC, Jichlinski P, Leisinger HJ, Benhattar J. Germ cell tumors of the testis overexpress wild-type p53. Am J Pathol 1996; 149:1221-8. [PMID: 8863671 PMCID: PMC1865176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Several recent studies have suggested that testicular germ cell tumors express high levels of wild-type p53 protein. To clarify and confirm this unexpected result, we have investigated seminomatous and nonseminomatous germ cell tumors at the genomic, mRNA, and protein levels. Thirty-five tumors were examined for p53 overexpression using antibodies directed against the p53 (PAb1801, PAb240, and CM1), mdm2 (IF2), and p21Waf1/Clp1 (EA10) proteins. Thirty-two tumors were screened for p53 mutations by single-strand conformation polymorphism analysis. Eighteen tumors were screened with a functional assay that tests the transcriptional competence of human p53 protein expressed in yeast. On frozen sections, 100, 65, 35, 73, and 0% of tumors reacted with the CM1, PAb240, PAb1801, IF2, and EA10 antibodies, respectively. No p53 mutations were detected by single-strand conformation polymorphism or by functional assay. The fact that many tumors overexpress wild-type p53 but not mdm2 rules out mdm2 overexpression as a general explanation for the presence of wild-type p53 in these tumors. The absence of p21 overexpression suggests that p53 may be unable to activate transcription of critical target genes, which may explain why the presence of wild-type p53 is tolerated in this tumor type, although the mechanism for this transcriptional inactivity remains to be established.
Collapse
Affiliation(s)
- L Guillou
- University Institute of Pathology of Lausanne, Switzerland
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Shaw P, Freeman J, Bovey R, Iggo R. Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. Oncogene 1996; 12:921-30. [PMID: 8632915] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The carboxy-terminus of p53 contains a basic region which represses DNA binding, and this repression can be relieved by PAb421, an antibody against the basic region. The EB-1 human cell line contains wild type p53 protein which fails to express the PAb421 epitope and is highly active both in biological assays and in DNA binding assays. We show by wheat germ agglutinin chromatography and galactosyl-transferase labelling that this p53 is O-glycosylated, and that at least one of the sugar residues masks the PAb421 epitope, as demonstrated by recovery of reactivity with PAb421 after digestion of Western blots of EB-1 cell extract with hexosaminidase. A minor population of p53 molecules in EB-1 cells lacks the modification, and there is a correlation between the ability to bind DNA with high affinity and masking of the PAb421 epitope. We also show that strongly positively charged peptides, including short peptides from the basic region of p53, can derepress DNA binding, probably by disruption of an intramolecular interaction involving the basic region. We propose that any intervention which prevents this intramolecular interaction, including addition of bulky residues such as sugar groups, can activate DNA binding by p53.
Collapse
Affiliation(s)
- P Shaw
- Swiss Institute for Experimental Cancer Research (ISREC), Lausanne, Switzerland
| | | | | | | |
Collapse
|
41
|
Flaman JM, Waridel F, Estreicher A, Vannier A, Limacher JM, Gilbert D, Iggo R, Frebourg T. The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene 1996; 12:813-8. [PMID: 8632903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Alternative splicing affecting the p53 carboxy-terminus has previously been described in mouse but not in normal human cells. We report here the detection in normal human lymphocytes of an alternatively spliced form of human p53 mRNA containing an additional 133 bp exon derived from intron 9. This splice variant encodes a truncated protein of 341 amino-acids including 10 new amino-acids derived from the novel exon. The truncated protein, which lacks part of the p53 tetramerization domain, fails to bind DNA in vitro and has a transcriptional defect in vivo in both yeast and mammalian cells. Quantitative RT-PCR experiments suggest that the alternatively spliced form is only present in significant amounts in quiescent cells. Considering the numerous functions ascribed to the carboxy-terminus of the p53 protein, this splice variant may have important implications for the biological role of p53 in normal cells.
Collapse
Affiliation(s)
- J M Flaman
- Laboratoire de Génétique Moléculaire, CHU de Rouen, France
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Abstract
The human p68, Saccharomyces cerevisiae DBP2 and Schizosaccharomyces pombe dbp2 genes are closely related members of the 'DEAD-box' RNA helicase superfamily. All three genes contain an intron at a conserved site in RNA helicase motif V. The S.cerevisiae intron is unusual both for its position near the 3'-end of the open reading frame and for its size, 1001 nucleotides. We show here that precise deletion of the intron has no effect on cell viability but leads to an increase in Dbp2p protein expression. Inefficient splicing due to the size of the intron can not account for this difference because the intron is efficiently spliced in Dbp2p-deficient cells. Instead, there is a reciprocal relationship between the amount of Dbp2p in the cell and the efficiency with which DBP2 intron-containing genes are expressed. Inactive Dbp2p mutants are efficiently expressed from DBP2 intron-containing plasmids, and fragments of the DBP2 intron confer Dbp2p-responsiveness on heterologous reporter introns. This suggest that there is an intron-mediated negative feedback loop regulating DBP2 expression, and provides a possible explanation for the retention of such an unusual intron in S.cerevisiae.
Collapse
Affiliation(s)
- I Barta
- Swiss Institute for Experimental Cancer Research (ISREC), Epalinges
| | | |
Collapse
|
43
|
Abstract
We have mutagenized human p53 expressed in yeast and selected two mutants, 121F and 123A, which activate transcription from one, rather than the normal two, copies of the consensus p53 DNA binding sequence. Both mutants have a 6-fold increase in affinity for a single copy of the sequence GGG CATG CCC. The 121F mutant has a decrease, and the 123A mutant an increase, in the affinity for the sequence GAA CATG TTC. This genetic and biochemical evidence supports the crystallographic finding that amino acid 120 contacts guanine in the major groove at the second position in the consensus. The major p53 binding site in the p21WAF1/CIP1 promoter resembles the GAA CATG TTC form of the consensus. Compared with wild type p53, the 121F mutant has a 7-fold lower affinity for the p21WAF1/CIP1 site in vitro, and the 121F mutant is defective in p21 induction in vivo. Mutants with subtly altered sequence specificity may facilitate dissection of downstream pathways activated by p53.
Collapse
Affiliation(s)
- J Freeman
- Swiss Institute for Experimental Cancer Research (ISREC), Epalinges
| | | | | | | |
Collapse
|
44
|
Affiliation(s)
- J M Flaman
- Unité de Génétique Moléculaire, CHU de Rouen, France
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Friend SH, Iggo R, Ishioka C, Fitzgerald M, Hoover I, O'Neill E, Frebourg T. Overcoming complexities in genetic screening for cancer susceptibility. Cold Spring Harb Symp Quant Biol 1994; 59:673-6. [PMID: 7587129 DOI: 10.1101/sqb.1994.059.01.077] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- S H Friend
- Massachusetts General Hospital Cancer Center, Charlestown 02129, USA
| | | | | | | | | | | | | |
Collapse
|
46
|
Ishioka C, Frebourg T, Yan YX, Vidal M, Friend SH, Schmidt S, Iggo R. Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet 1993; 5:124-9. [PMID: 8252037 DOI: 10.1038/ng1093-124] [Citation(s) in RCA: 174] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Inherited mutations of the p53 gene significantly increase the risk of developing diverse malignancies, and germline p53 mutations can be detected by assaying the transcriptional activity of the p53 protein in mammalian cells. Here we describe a method starting with lymphocytes that allows detection of germline p53 mutations by 'functional' analysis of p53 protein expressed in Saccharomyces cerevisiae. The p53 PCR products are directly cloned into yeast expression vectors in vivo and subsequently tested for transcriptional activity in a simple growth assay. This technique, functional analysis of separated alleles in yeast (FASAY), requires only a few steps, can be automated readily and should permit screening for germline or somatic heterozygous mutations in any gene whose function can be monitored in yeast.
Collapse
Affiliation(s)
- C Ishioka
- Massachusetts General Hospital Cancer Center, Charlestown 02129
| | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
p53 has previously been shown to contain a transactivation domain using GAL4 fusion proteins and to bind specifically to a 33 base pair DNA sequence in immunoprecipitation assays. We show here that mammalian p53 expressed in S. cerevisiae is able to activate transcription of a reporter gene placed under the control of a CYC1 hybrid promoter containing the 33 base pair p53-binding sequence. The activation is dependent on the orientation and number of copies of the binding site. Three p53 mutants commonly found in human tumours, 175H, 248W and 273H, are unable to activate transcription. A fourth human p53 mutant, 285K, is temperature-sensitive for transcriptional activation. Murine p53 activates transcription from the same sequence. The murine 135V mutant, which is temperature-sensitive for mammalian cell transformation, is also temperature-sensitive for transcriptional activation. There is a much better correlation between mutation and transcriptional competence than between mutation and the structure of p53 determined with conformation-sensitive antibodies. We have therefore developed a simple transcription assay for p53 mutation in which yeast are transfected with p53 PCR products and mutation is scored on X-gal plates.
Collapse
Affiliation(s)
- E Schärer
- Swiss Institute for Experimental Cancer Research, ISREC, Epalinges
| | | |
Collapse
|
48
|
Abstract
The human p68 protein, an SV40 large T related antigen, is an RNA dependent ATPase and RNA helicase. It belongs to a new large and highly conserved gene family, the DEAD box proteins, whose members are involved in a variety of processes requiring manipulation of RNA secondary structure such as translation and splicing. Multiple DEAD box genes are present in S.cerevisiae, but only one has previously been described in E.coli. Low stringency screening of an E.coli genomic library with a p68 cDNA probe led to the identification of dbpA, a new E.coli DEAD box gene located at 29.6 minutes on the W3110 chromosome. We report here the nucleotide and deduced amino acid sequences of the gene. We have overexpressed dbpA from its own promoter on a high copy number plasmid and identified the gene product as a approximately 50 kD protein by immunoblotting with an anti-DEAD antibody.
Collapse
Affiliation(s)
- R Iggo
- Imperial Cancer Research Fund, Clare Hall Laboratories, South Mimms, Herts, UK
| | | | | | | | | |
Collapse
|
49
|
Bartek J, Iggo R, Gannon J, Lane DP. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990; 5:893-9. [PMID: 1694291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The expression of the tumour suppressor gene p53 was analysed in 11 human breast cancer cell lines by immunohistochemistry, immunoprecipitation and cDNA sequencing. We used a panel of anti-p53 monoclonal antibodies for cell staining and found abnormalities in every case. Eight of the cell lines produce a form of p53 which can be immunoprecipitated by the monoclonal antibody PAb240 but not by PAb1620. In the murine system PAb240 only immunoprecipitates mutant p53. We sequenced p53 cDNA directly from four of the PAb240 positive cell lines using asymmetric PCR templates. All four contained missense mutations in p53 RNA, with no detectable expression of the wild type sequence. Different residues were affected in each cell line, but all the mutations changed amino acids conserved from man to Xenopus. These results imply that as in the murine system, the PAb240 antibody reliably detects a wide variety of p53 mutations and that these mutations have a common effect on the structure of p53. Immunohistochemical data suggest that p53 mutation is the commonest genetic alteration so far detected in primary breast cancer.
Collapse
MESH Headings
- Amino Acid Sequence
- Antibodies/immunology
- Breast Neoplasms/genetics
- Breast Neoplasms/metabolism
- Breast Neoplasms/pathology
- Carcinoma, Intraductal, Noninfiltrating/genetics
- Carcinoma, Intraductal, Noninfiltrating/metabolism
- Carcinoma, Intraductal, Noninfiltrating/pathology
- DNA, Neoplasm/genetics
- DNA, Neoplasm/metabolism
- Epitopes/immunology
- Gene Expression
- Humans
- Immunohistochemistry
- Molecular Sequence Data
- Mutation
- Oncogene Proteins/genetics
- Oncogene Proteins/immunology
- Oncogene Proteins/metabolism
- Phosphoproteins/genetics
- Phosphoproteins/immunology
- Phosphoproteins/metabolism
- Polymerase Chain Reaction
- Precipitin Tests
- RNA, Neoplasm/genetics
- RNA, Neoplasm/metabolism
- Transcription, Genetic
- Tumor Cells, Cultured/metabolism
- Tumor Cells, Cultured/pathology
- Tumor Suppressor Protein p53
Collapse
Affiliation(s)
- J Bartek
- ICRF Molecular Immunochemistry Laboratory, Clare Hall Laboratories, Potters Bar, Herts, UK
| | | | | | | |
Collapse
|
50
|
Abstract
Point mutations in the p53 gene are the most frequently identified genetic change in human cancer. They convert murine p53 from a tumour suppressor gene into a dominant transforming oncogene able to immortalize primary cells and bring about full transformation in combination with an activated ras gene. In both the human and murine systems the mutations lie in regions of p53 conserved from man to Xenopus. We have developed a monoclonal antibody to p53 designated PAb240 which does not immunoprecipitate wild type p53. A series of different p53 mutants all react more strongly with PAb240 than with PAb246. The PAb240 reactive form of p53 cannot bind to SV40 large T antigen but does bind to HSP70. In contrast, the PAb246 form binds to T antigen but not to HSP70. PAb240 recognizes all forms of p53 when they are denatured. It reacts with all mammalian p53 and chicken p53 in immunoblots. We propose that immunoprecipitation of p53 by PAb240 is diagnostic of mutation in both murine and human systems and suggest that the different point mutations which convert p53 from a recessive to a dominant oncogene exert a common conformational effect on the protein. This conformational change abolishes T antigen binding and promotes self-oligomerization. These results are consistent with a dominant negative model where mutant p53 protein binds to and neutralizes the activity of p53 in the wild type conformation.
Collapse
Affiliation(s)
- J V Gannon
- Molecular Immunochemistry Laboratory, Imperial Cancer Research Fund, Potters Bar, Herts, UK
| | | | | | | |
Collapse
|